Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TITAN PHARMACEUTICAL (TTP) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (142)	10/5/2000 2:34:48 AM
From: sim1	Read Replies (1) \| Respond to of 362

>>One monthly [Zomaril] depo formulation? Anyone with idea whose this technology is?<< I was wondering if it's possible for it to be some early version of their own (TTP) technology. From their 10k... IMPLANTABLE DRUG DELIVERY SYSTEM We are developing a sustained drug delivery technology with application in the treatment of a number of neurologic and psychiatric disorders in which conventional treatment is limited by variability of drug concentration in blood and poor patient compliance. The technology, which has been licensed from the Massachusetts Institute of Technology (MIT), consists of a polymeric drug delivery system that potentially can provide controlled drug release over extended periods (i.e., from three months to more than one year). The technology involves imbedding the drug of interest in a polymer, which is then implanted subcutaneously to provide systemic delivery as body fluids wash over the implant and the drug is released. This results in a constant rate of release similar to intravenous administration. We believe that such long-term, linear release characteristics are highly desirable, avoiding peak and trough level dosing that poses problems for many CNS and other therapeutic agents. In July 1999, we announced that our ProNeura subsidiary had successfully completed pre-clinical experiments demonstrating long-term drug delivery using its polymeric drug delivery system. This study, which was supported by an SBIR phase I grant from the National Institutes of Health (NIH), demonstrated proof of concept in animal models using an approved antipsychotic agent, by delivering sustained therapeutic drug levels for periods of greater than four months, without any adverse effects. We are conducting further pre-clinical evaluation of prototype products through contract research and manufacturing organizations, including evaluation of this drug delivery system for treatment of drug addiction. This project is currently supported by an SBIR grant. We currently own approximately 79% of ProNeura.